Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC vs Sequential T-AC in Node Positive Breast Cancer
NCT00525642Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by Fudan University. Primary endpoints: Disease Free Survival at 10 years and Grade III/IV Adverse Event, Severe Adverse Event. Status: unknown.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00525642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525642.